A case of Hepato cellular carcinoma maintained a long partial response by low dose sorafenib with sever chronic renal dysfunction

Yuji Ishihara, Naomi Sugimura, Noriyuki Horiguchi, Koki Asukai, Hiroki Koguchi, Yusuke Inoue, Shozo Togawa, Izumi Hasegawa, Kenji Sakakibara, Tomoyoshi Ohno

研究成果: Article査読

抄録

A 65-year-old male with HCV-positive hepato cellular carcinoma (HCC) and right renal cell carcinoma was simultaneously treated by surgical resection. During follow-up, a solitary recurrence was found and cured by the radiofrequency ablatioa but around then chronic renal failure as a complication of diabetes mellitus was getting worse up to 5.39 mg/dl at the serum creatinine, abbreviated as sCr below, and considered to introduce into hemodialysis (HD). However, MRI examination revealed multiple recurrence of liver, the plan of introducing into HD was quitted and the interventional therapy under the angiography was also given up. As the patient's liver function was the level of Child-Pugh A, the treatment with solafenib was made a plan in hospital After admitted he was treated with sorafenib at a starting dose of 400 mg/day in consideration of renal dysfunction Seven days after initiation, the dose was reduced to 200 mg/day because of appearing the grade 3 level of diarrhea. At 5 months after the administration of sorafenib, tumor markers, of which AFP and PIVKA-II were maximally at 3774 ng/ml and 14995 mAU/ml respectively were remarkably decreased to the normal level. MRI examination demonstrated the reduction of HCCS in size, and the therapeutic effect was considered as partial response by Response Evaluation Criteria in Solid tumors (RESIST). The enhanced ultra sonography showed no sign of blood flow in all of tumors, suggesting as a remarkable response to sorafenib. Of notice, the level of sCr was gradually down after use of sorafenib (sCr: 1.45 mg/dl at March-13). Sorafenib treatment has been continued with dose of 200 mg/day, and the tumor markers have been kept within normal limit even now.

本文言語English
ページ(範囲)529-534
ページ数6
ジャーナルActa Hepatologica Japonica
54
8
DOI
出版ステータスPublished - 2013
外部発表はい

All Science Journal Classification (ASJC) codes

  • Hepatology

フィンガープリント 「A case of Hepato cellular carcinoma maintained a long partial response by low dose sorafenib with sever chronic renal dysfunction」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル